Cardiac Events with Gleevec (Feb. 2007)


Novartis is notifying healthcare professionals about new precautions for Gleevec (imatinib mesylate). Gleevec is used to treat certain patients with chronic myeloid leukemia and gastrointestinal stromal tumors.A recent article published in Nature Medicine reported on ten patients taking Gleevec who developed severe congestive heart failure and left ventricular dysfunction. Before starting treatment, most of these patients had
pre-existing conditions such as hypertension, diabetes and
coronary artery disease. The article also reported on preclinical studies showing that mice treated with the drug developed left ventricular contractile dysfunction.

Novartis has now added a precaution to the drug labeling about severe congestive heart failure and left ventricular dysfunction. The company also says that patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Additional Information:

FDA MedWatch Safety Alert - Gleevec (imatinib mesylate) -- October 19, 2006.
http://...







Channel: News
Uploaded: May 6, 2008 at 11:17 am
Author: LawsuitGuru

Length: 00:01:08
Rating: 4.00
Views: 217

Tags: Tumors Heart FDA Gastrointestinal Cardiac Failure Events Imatinib Gleevec Stromal Leukemia Mesylate Congestive Myeloid

Embed Code:


Video Comments:
No Comment
 

Privacy Policy Cancer Video | Treatment Survival & Education Copyright © 2007 All Rights Reserved.